Kinase News and Research

RSS

New research on molecular mechanistic understanding of drug delivery and drug delivery systems

Today, Insilico Medicine, Inc., a Rockville-based next-generation artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research announces the publication of a new research paper "Entangled Conditional Adversarial Autoencoder for de-novo Drug Discovery" in Molecular Pharmaceutics, the leading American Chemical Society journal covering research on the molecular mechanistic understanding of drug delivery and drug delivery systems

12 Sep 2018

Gene involved in circadian rhythms can be potential target for glioblastoma treatment

Scientists with the Virginia Tech Carilion Research Institute say a gene involved in the body's circadian rhythms is a potential target for therapies to help patients with a deadly form of brain cancer known as glioblastoma.

11 Sep 2018

Blocking RNA-silencing protein in the liver prevents obesity and diabetes in mice

Obesity and its related ailments like type 2 diabetes and fatty liver disease pose a major global health burden, but researchers report in Nature Communications that blocking an RNA-silencing protein in the livers of mice keeps the animals from getting fat and diabetic conditions.

11 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Verastem, Inc., operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

6 Sep 2018

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a clinical-stage rare disease and oncology company focused on sourcing and developing innovative treatments for underserved patient populations, announced today that the companies have entered into a global clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene's investigational RAF dimer inhibitor, lifirafenib and SpringWorks Therapeutics' investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors.

6 Sep 2018

Researchers make discovery about yeast metabolism that could help drug developers

Researchers at the Francis Crick Institute have developed machine learning algorithms that can predict the metabolism of yeast based on its protein content.

6 Sep 2018

Researchers identify enzyme that plays vital role in sexual development of fungi

Biologists at Ruhr-Universität Bochum and Georg-August-Universität Göttingen have gained new insights into specific enzymes that effect the specialization of fungal cells.

5 Sep 2018

Scientists identify 'Achilles heel' of anaplastic large-cell lymphomas

Anaplastic large-cell lymphomas are rare cancers of the white blood cells. New research from the international ERIA consortium, led by scientists in Vienna, has now shown that the same signaling pathway is essential to the growth of cancer cells in various forms of ALCL: TYK2 (tyrosine kinase 2, an important component of the immune system) prevents apoptotic cell death by increasing the production of Mcl1, a special type of protein belonging to the BCL2 family.

3 Sep 2018

New project investigates impact of thymectomy as treatment for MuSK myasthenia gravis

The American Association of Neuromuscular & Electrodiagnostic Medicine is honoring Katherine Clifford, BA, with the 2018 Golseth Young Investigator Award for her abstract, Thymectomy is Not Associated With Clinical Improvement in a Multi-Center Cohort of Patients with Anti-MuSK Myasthenia Gravis.

3 Sep 2018

Genetic mutations may drive tumor formation by blurring growth signals

Genetic mutations in a form of non-small cell lung cancer (NSCLC) may drive tumor formation by blurring cells' perception of key growth signals, according to a new laboratory study published August 31, 2018 in Science.

3 Sep 2018

Researchers discover potential new approach to block growth of HER2 positive breast cancer

Researchers at Mayo Clinic have identified an important new pathway by which HER2 positive breast cancers grow and have discovered that a dietary supplement called cyclocreatine may block the growth of HER2 positive breast cancer.

30 Aug 2018

Research shows proteomics can be used to predict evolution of triple negative breast cancer

The rarest, but also the most aggressive and hard to treat form of breast cancer, is known as triple negative. For this type of cancer, researchers have so far been unable to identify markers that can classify patients by prognosis or probability of responding to different treatments.

29 Aug 2018

Pediatric researchers discover gene mutation that causes lymphatic disorder

Pediatric researchers have identified a gene mutation that causes a serious lymphatic condition, and used that knowledge to restore normal lymphatic vessels in model animals. The laboratory findings may lead to a new therapy for patients with this type of abnormal lymphatic circulation.

28 Aug 2018

Researchers launch clinical trial to assess new drug combination against metastatic breast cancers

Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed.

28 Aug 2018

Inhibition of miR-24-3p may serve as potential treatment target for mesothelioma

Inhibition of miR-24-3p reduced growth of cancer cells and was found to regulate proteins as a potential treatment target for Mesothelioma.

25 Aug 2018

Scientists identify molecular pit crew responsible for refueling in signaling cells

During IndyCar races, pit stop crews will often refuel a car, replace wheels and complete minor repairs on a race car within 10 seconds. In this short time, a dozen or so people work rapidly and in a highly coordinated manner to complete a number of tasks with extraordinary efficiency.

24 Aug 2018

MDA announces 34 new grants totaling $9.9 million to accelerate neuromuscular research

The Muscular Dystrophy Association today announced the award of 34 new grants totaling more than $9.9 million for its summer round of funding. These new grants represent a continued commitment by MDA to fund groundbreaking research that will accelerate treatments and cures for the more than 40 diseases in its program.

24 Aug 2018

Researchers complete testing a new drug to treat rheumatoid arthritis

An international research group led by Charité - Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

23 Aug 2018

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.

23 Aug 2018

Kinase News and Research

New research on molecular mechanistic understanding of drug delivery and drug delivery systems

Gene involved in circadian rhythms can be potential target for glioblastoma treatment

Blocking RNA-silencing protein in the liver prevents obesity and diabetes in mice

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

Researchers make discovery about yeast metabolism that could help drug developers

Researchers identify enzyme that plays vital role in sexual development of fungi

Scientists identify 'Achilles heel' of anaplastic large-cell lymphomas

New project investigates impact of thymectomy as treatment for MuSK myasthenia gravis

Genetic mutations may drive tumor formation by blurring growth signals

Researchers discover potential new approach to block growth of HER2 positive breast cancer

Research shows proteomics can be used to predict evolution of triple negative breast cancer

Pediatric researchers discover gene mutation that causes lymphatic disorder

Researchers launch clinical trial to assess new drug combination against metastatic breast cancers

Inhibition of miR-24-3p may serve as potential treatment target for mesothelioma

Scientists identify molecular pit crew responsible for refueling in signaling cells

MDA announces 34 new grants totaling $9.9 million to accelerate neuromuscular research

Researchers complete testing a new drug to treat rheumatoid arthritis

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News